1. Home
  2. ARVN vs IFN Comparison

ARVN vs IFN Comparison

Compare ARVN & IFN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ARVN
  • IFN
  • Stock Information
  • Founded
  • ARVN 2015
  • IFN 1993
  • Country
  • ARVN United States
  • IFN Singapore
  • Employees
  • ARVN 430
  • IFN N/A
  • Industry
  • ARVN Biotechnology: Pharmaceutical Preparations
  • IFN Finance/Investors Services
  • Sector
  • ARVN Health Care
  • IFN Finance
  • Exchange
  • ARVN Nasdaq
  • IFN Nasdaq
  • Market Cap
  • ARVN 676.2M
  • IFN 595.7M
  • IPO Year
  • ARVN 2018
  • IFN N/A
  • Fundamental
  • Price
  • ARVN $9.45
  • IFN $15.36
  • Analyst Decision
  • ARVN Buy
  • IFN
  • Analyst Count
  • ARVN 23
  • IFN 0
  • Target Price
  • ARVN $17.61
  • IFN N/A
  • AVG Volume (30 Days)
  • ARVN 2.6M
  • IFN 135.2K
  • Earning Date
  • ARVN 11-04-2025
  • IFN 01-01-0001
  • Dividend Yield
  • ARVN N/A
  • IFN 8.68%
  • EPS Growth
  • ARVN N/A
  • IFN N/A
  • EPS
  • ARVN N/A
  • IFN N/A
  • Revenue
  • ARVN $372,800,000.00
  • IFN N/A
  • Revenue This Year
  • ARVN $1.01
  • IFN N/A
  • Revenue Next Year
  • ARVN N/A
  • IFN N/A
  • P/E Ratio
  • ARVN N/A
  • IFN N/A
  • Revenue Growth
  • ARVN 299.57
  • IFN N/A
  • 52 Week Low
  • ARVN $5.90
  • IFN $14.40
  • 52 Week High
  • ARVN $29.61
  • IFN $21.25
  • Technical
  • Relative Strength Index (RSI)
  • ARVN 57.54
  • IFN 61.17
  • Support Level
  • ARVN $9.01
  • IFN $14.98
  • Resistance Level
  • ARVN $9.55
  • IFN $15.47
  • Average True Range (ATR)
  • ARVN 0.49
  • IFN 0.18
  • MACD
  • ARVN -0.10
  • IFN 0.06
  • Stochastic Oscillator
  • ARVN 44.37
  • IFN 87.22

About ARVN Arvinas Inc.

Arvinas Inc is a United States-based biopharmaceutical company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development and commercialization of therapies that degrade disease-causing proteins.. The company's proprietary Proteolysis-Targeting Chimera (PROTAC), work by inducing the cell's own ubiquitin-proteasome system to target, degrade and remove disease-causing proteins. The group's product candidates are bavdegalutamide, ARV-471 and ARV-766.

About IFN India Fund Inc. (The)

India Fund Inc is an asset management company. The fund's investment objective is long-term capital appreciation, which it seeks to achieve by investing in the equity securities of Indian companies. The company's portfolio is a non-diversified closed-end management investment company across various sectors such as financials, consumer staples, information technology, materials, healthcare, consumer discretionary, industrials, telecommunication services, utilities, and others. Geographically, all the business activity functions through the market of the United States.

Share on Social Networks: